Skip to Main Content

Paper Details

Preclinical evaluation of the PARP inhibitor BMN-673 for the treatment of ovarian clear cell cancer.
Oncotarget
12
2017
Author NameAffiliation
Maryou B LambrosThe Breakthrough Breast Cancer Research Centre, Institute of Cancer Research
Salvatore PiscuoglioMemorial Sloan Kettering Cancer Center
Britta WeigeltMemorial Sloan Kettering Cancer Center
Jorge S Reis-FilhoThe Breakthrough Breast Cancer Research Centre, Institute of Cancer Research
Jorge S Reis-FilhoMemorial Sloan Kettering Cancer Center
  • 1 - 5

Datasets

Release 1.2